Not Alzheimer's?
Our services are also for these related disorders.

Alzheimer's Association, New York City Chapter

  • 24-hour helpline: 800.272.3900
  • Translation available in 140 languages
  • Click here to contact us

 

Search
Join Us! On Facebook! On Twitter! On MySpace! On YouTube! On Digg! 
 
Select a Topic
Cover
Calling All Baby Boomers
President's Message
From the
Program Director
Workshop For Chaplains
From the Editor's Desk
"Forget-Me-Not" Gala
MedicAlert + Safe Return
Early-Stage Services
Chapter Snapshots
Della's Space
Dementia Home Care Training Graduations
In Our Own Words
Diversity &
Outreach Updates
Reflections
Dr. Bob Green
F.Y.I
What to Expect from an AD/ Dementia Assessment/Evaluation
If It's Not Alzheimer's:
Wernicke-Korsakoff Syndrome
Dear Helpline
Caregivers' Corner
Caregiver Profile
Residential Care
Alzheimer's In The News
Chapter In The News
Public Policy Update
Legal Guidance
Book Shelf
Volunteer Corner
Women In Action
Junior Committee Update
Development
Ways To Give
Development Report
Development
Cultivation Event
Development
Meet Our Donors
N.Y.C.A.R.E.
The Role of Diet in Reducing Risk of Alzheimer's Disease
Clinical Trials
Columbia University Clinical Trials
NYU Clinical Trials
Mt. Sinai Clinical Trials
ALZ NYC Online Store
Memory Walk 2008!
Bulletin Board
Know Your Charity
HonorGift Tribute Cards
Chapter Staff
Board of Directors
Education Calendar
Support Groups

En Español
Archived Versions
Featured Articles Index
 
 
 
   
 
Clinical Trials
 
Text Size A  A  A


Columbia University Medical Center • Taub Institute

Clinical Trials

Receptor for Advanced Glycation Endproducts (RAGE) in Alzheimer’s Disease

We are seeking men and women age 50 and older with mild-to-moderate Alzheimer’s disease to participate in a Phase II study of a drug that blocks the receptor for advanced glycation endproducts, which damages nerve cells in the brain. This study will last 21 months. For more information, please contact Ruth Tejeda at 212-305-7661.

 

Study of Oral ELND005 (AZD-103) in Mild-to-Moderate Alzheimer’s Disease (AD)

We are currently screening participants for this Phase II study of an oral compound which researchers hope will prevent the formation of amyloid protein clusters in the brain and perhaps shrink the clusters that are already there. English- and Spanish-speaking individuals diagnosed with probable AD who are between the ages of 50 and 85 inclusive may be eligible to participate. For more information, please contact Lynda Mules at 212-305-2077 or lm2538@columbia.edu.

 

Study of Bapineuzumab (AAB-001, ELN15727) in Mildto- Moderate Alzheimer’s Disease (AD)

This is a Phase III study of bapineuzumab administered by IV infusion which researchers hope will attach to the amyloid protein in the brain and help the body to remove it. Individuals diagnosed with probable AD who are 50 to 88 years old may be eligible to participate. For more information, please contact Evelyn Dominguez at 212-305-2371 or edd5@columbia.edu

 

Effect of Gamma-Secretase Inhibition on the Progression of Alzheimer’s Disease (AD)

This is a Phase III study of the effect of LY45013, an oral compound, on the progression of AD. Men and women age 55 and older with mild-to-moderate AD may be eligible to participate. For more information, please contact Lynda Mules
at 212-305-2077 or lm2538@columbia.edu.

 

Metformin in Amnestic Mild Cognitive Impairment (MCI)

This study, funded by the Institute for the Study of Aging, is a clinical trial of metformin, a medication effective in the prevention and treatment of diabetes. The basis for this study is that persons with diabetes, and persons at risk of diabetes, could have a higher risk of Alzheimer’s disease. Thus, we seek to test this medication vs. a similar pill without effects (placebo) in persons with MCI, a condition in which persons have memory complaints and detectable memory deficits on testing. To be eligible for this study, persons must be overweight or obese, over the age of 55 years, and have memory complaints. The study will last 12 months. For further information, please contact Dr. Jose Luchsinger
at 212-305-4730 or jal94@columbia.edu.

 

Antipsychotic Medication Treatment of Psychosis and Behavioral Dyscontrol
in Alzheimer’s Disease (AD)

This research study, funded by the National Institute of Aging, uses risperidone (an FDA-approved antipsychotic medication) to treat people with AD who suffer from hallucinations, delusions, agitation, and/or aggression. Treatment continues over a period of 48 weeks. Each eligible participant must have a family member or caregiver who can assist with adherence to treatment and provide information during the research study. For further information, please contact Michelle Motta
at 212-543-6132
.

 

Antidepressant Treatment Studies for Combined Depression and Memory Complaints

We are currently conducting medication treatment studies for individuals (age 50+) experiencing both depression and mild memory and/or concentration difficulties. The studies offer both neuropsychological testing for memory and psychiatric evaluation of mood prior to and during the period of treatment. Treatment in our clinic is provided for eligible individuals at no cost for at least 6 months. For further information, please contact Karine Cunqueiro at 212-543-5067.

 

Study of Memantine in Frontotemporal Dementia

This is a Phase IV study to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia (FTD). English-speaking men and women aged 40 to 80 who have been diagnosed with FTD or semantic dementia (SD) may be eligible to participate. For further information, please contact Lynda Mules
at 212-305-2077
or lm2538@columbia.edu.

 

NEUROIMAGING STUDIES

Alzheimer’s Disease (AD) PET Scan Study

This study explores whether a novel imaging agent used during a Positron Emission Tomography (PET) scan can confirm an AD diagnosis while the patient is alive. This would be useful for diagnosing AD, evaluating the effects of different drugs, allowing doctors to diagnose AD earlier, and identifying subjects at risk for developing AD. We are seeking individuals older than 50 years of age (females must no longer be of childbearing potential) who are in good general health with no memory problems OR who do have a diagnosis of AD. Participants must be fluent in English, must be willing and able to undergo the test procedures, and must have a study partner who is willing to answer a few questions. For more information please contact Oksana Tatarina at 212-305-1987 or Linda Sanders at 212-342-0522.

 

Brain Imaging Study Measuring Changes in Cerebral Blood Flow and Cognition with Age

This study uses brain-imaging technology to assess cerebral blood flow pattern in elderly individuals using Magnetic Resonance Imaging (MRI). We are seeking healthy individuals and patients with memory complaints or with Alzheimer’s disease (AD), age 55 to 85. Participants will receive MRI and memory testing. This study uses Arterial Spin Labeling (ASL), a technique that uses MRI to measure cerebral blood flow in the brain. No injection of any tracer is necessary, since ASL-MRI uses the water inherent in the body as a tracer. Our aim is to use blood flow pattern in the brain as a possible diagnostic marker of early AD. The study consists of three visits and participants will receive compensation. For further information, please contact Brittany Holmes at 212-395-7846 or bsh2114@columbia.edu.

 

PET Scan Study for People with Parkinson’s Disease, Dementia with
Lewy Body Disease, Alzheimer’s Disease, and Healthy Volunteers

We are seeking English-speaking men and women age 50 to 95 who have either Parkinson’s disease, Dementia with Lewy Body disease, Alzheimer’s disease, or are healthy without memory problems. Participants will receive a Positron Emission Tomography (PET) scan that uses a radioactive tracer to bind to a dopaminergic transporter. This tracer may serve as an agent for in vivo imaging of dopaminergic degeneration in patients with different neurodegenerative diseases. Standard clinical procedures will be done including memory testing, blood work, and an MRI scan. The study consists of two visits, and participants will receive compensation. For futher information, please contact Linda Sanders
at 212-342-0522 or Oksana Tatarina at 212-305-1987
.

 

Brain Imaging Study of Smell Function in Healthy Individuals and Patients
with Memory Complaints

This study uses brain-imaging procedures to understand how aging and Alzheimer’s disease (AD) affect smell function. Healthy individuals and patients with memory complaints or with AD receive a Functional Magnetic Resonance Imaging (fMRI) scan while smelling common odors (e.g., coffee). Similar to standard MRI, which looks at brain structures, fMRI uses magnetic fields and radio waves to look at how the brain is functioning. This study will help us to understand the changes that occur in brain activity with age and disease progression. For further information, please contact Matt Tabert, Ph.D.,
at 212-543-5046
.

 

OTHER STUDIES

Genetic Linkage Study

We are seeking families of all nationalities and backgrounds for a study that seeks to identify genes that may increase the risk for developing Alzheimer’s disease (AD). If your family has at least two living siblings diagnosed with AD who are 60 years old or older, please call Vincent Santana at 800-243-5828 or Jennifer Williamson at 212-305-4655.

 

Memory Problems II: Course and Predictors of Outcome

This research study for people ages 55-90, with and without memory complaints, includes medical evaluation by physicians who specialize in memory disorders and neuropsychological testing to assess memory & intellectual functions. Medical evaluation and neuropsychological testing with close monitoring will take place annually for 7 years. At the initial visit only, an MRI scan, two PET scans and a lumbar puncture will be performed. Participants are reimbursed $150 for both PET scans, $50 for the MRI scan, and $50 for the lumbar puncture. Participants may also be compensated for time and travel. For more information, please call 212-543-5025.

 

ADDITIONAL INFORMATION

Brain Donation Program “Give the Gift of Knowledge”

Brain donation allows valuable information to be obtained regarding normal aging and diseases that affect memory. This information may be useful toward the goal of developing more effective treatment strategies. If you or a family member wish to learn more about this program, please call Arlene Lawton, RN, at 212-305-9086.

 

Lucy G. Moses Center for Memory and Behavioral Disorders

Changes in memory and thinking abilities can occur from a variety of conditions, not just Alzheimer’s disease. Taub Institute specialists offer a thorough multidisciplinary evaluation of memory and thinking difficulties at two locations:;

The Neurological Institute, 710 West 168th Street, New York, NY 10032

Columbia Presbyterian Eastside, 16 East 60th Street, New York, NY 10022

For appointments, call 212-305-6939.

Previous | Next

 
 
  Donate | About this Site | Security | Privacy Policy | Disclaimer | Staff Login


Shop For Our Cause Wise Giving Alliance Standard
Seal of Approval